Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 19/20 | 0.52 |
| ▸ | DDB1 | Q16531 | 8/20 | 0.46 |
| ▸ | CSNK1A1 | P48729 | 2/20 | 0.40 |
| ▸ | BRD4 | O60885 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 1/20 | 0.37 |
| ▸ | GSPT1 | P15170 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.35 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.35 |
| ▸ | IKZF3 | Q9UKT9 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1424456 | 0.93 | CRBN (0.47) | CRBNDDB1CSNK1A1GSPT1ALDH1A1 | |
| SCHEMBL1424747 | 0.92 | CRBN (0.47) | CRBNDDB1CSNK1A1GSPT1IKZF3 | |
| SCHEMBL1424240 | 0.91 | CRBN (0.46) | CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL1424344 | 0.91 | CRBN (0.45) | CRBNDDB1CSNK1A1RAB9AGSPT1 | |
| SCHEMBL1424713 | 0.91 | CRBN (0.45) | CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL1424368 | 0.90 | CRBN (0.47) | CRBNDDB1CSNK1A1BRD4RAB9A | |
| SCHEMBL1424695 | 0.90 | CRBN (0.46) | CRBNDDB1CSNK1A1GSPT1 | |
| SCHEMBL1424269 | 0.89 | CRBN (0.44) | CRBNDDB1CSNK1A1BRD4RAB9A | |
| SCHEMBL1424351 | 0.89 | CRBN (0.45) | CRBNDDB1CSNK1A1RAB9AGSPT1 | |
| SCHEMBL1424480 | 0.88 | POLB (0.44) | CRBNCSNK1A1BRD4RAB9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | CELGENE CORPORATION (US) | 2014-04-24 | — | — | US | disclosed |
| US-8648096-B2 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION (US) | 2014-02-11 | — | — | US | disclosed |
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | CELGENE CORPORATION | 2008-09-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214615-A1 | N-methylaminomethyl isoindole compounds and compositions comprising and methods of using the same | INMT, HNMT, TPMT | CRBN 3001/4885DDB1 3723/4885CSNK1A1 136/4885 |
| US-20140113935-A1 | N-METHYLAMINOMETHYL ISOINDOLE COMPOUNDS AND COMPOSITIONS COMPRISING AND METHODS OF USING THE SAME | INMT, HNMT, TPMT | CRBN 3001/4885DDB1 3723/4885CSNK1A1 136/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.